logo
Why the global balance of power is shifting in China's favour

Why the global balance of power is shifting in China's favour

In recent years, the world has entered an acute phase of geopolitical confrontation, driven by structural problems such as trade imbalances. Historically, such crises have often been addressed through military conflicts aimed at weakening rivals and redirecting financial and trade flows. This logic is examined in The Price of War, a study of conflicts spanning over 150 years.
Advertisement
Since most major powers today possess weapons of mass destruction for deterrence, confrontation has largely taken on a hybrid form. Yet the United States' drive to solve domestic problems at others' expense remains, especially in its relations with China, Russia and the European Union. The toolbox of weapons has expanded to include economic tools such as
tariffs or tech restrictions designed to limit the development of highly value-added industries.
The White House might be confident about this arsenal, but US President Donald Trump's policies of tariffs, tax cuts and
pressure on the US Federal Reserve have coincided with a
weakening US dollar . Meanwhile, efforts to reduce the trade deficit have diminished both Washington's global role and overall investor confidence.
The US dollar remains Washington's key economic weapon. But its declining status weakens US geopolitical influence. Since 2000, the US dollar's share in global reserves has fallen from 71 per cent to below 60 per cent. A recent study by the International Monetary Fund suggests that in times of rising global tension, countries diversify their currency holdings.
The S&P 500's
record performance , when measured in other major currencies, reveals a shift in the global financial system. Recent events are dispelling the illusion of US economic invincibility.
Advertisement
These trends are especially clear when viewed through a multidimensional national power index based on dozens of indicators such as demographics, technology, economy and military strength. My team at the Central Economics and Mathematics Institute of the Russian Academy of Sciences has developed a method to rank countries based on power.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why some Chinese students are skipping elite universities amid job market fears
Why some Chinese students are skipping elite universities amid job market fears

South China Morning Post

time19 minutes ago

  • South China Morning Post

Why some Chinese students are skipping elite universities amid job market fears

After underperforming in China's national college entrance exam in June, Lu Jie was accepted into a computer science and technology programme earlier this month at a lesser-known polytechnic university in central China's Hunan province. 'Good schools had too many applicants for this major, so I had to choose a lower-ranked one to pursue it,' Lu said. The results for the exam, better known as the gaokao , have been released over the past two weeks – marking a life-changing moment for students like Lu. Now more than ever, students are opting for majors with strong job prospects over prestigious universities. A focus on immediate employability and job security is eclipsing long-term aspirations and personal interests. Driving this trend is a growing oversupply of college graduates , intensifying competition in the job market amid a challenging economic climate. Computer science has long been a highly popular major, Lu said, but the rise of artificial intelligence (AI) – widely expected to create new job opportunities – has fuelled even greater demand over the past couple of years.

Looming US troop cuts in Europe raise questions about Nato's future
Looming US troop cuts in Europe raise questions about Nato's future

South China Morning Post

time2 hours ago

  • South China Morning Post

Looming US troop cuts in Europe raise questions about Nato's future

After keeping Donald Trump happy with a pledge to up defence spending at Nato's summit, Europe is now bracing for a key decision from the US president on the future of American forces on the continent. Advertisement Washington is currently conducting a review of its military deployments worldwide – set to be unveiled in the coming months – and the expectation is it will lead to drawdowns in Europe. That prospect is fraying the nerves of US allies, especially as fears swirl that Russia could look to attack a Nato country within the next few years if the war in Ukraine dies down. However, the alliance is basking in Trump's new-found goodwill following its June summit in The Hague, and his officials are making encouraging noises that Europe will not be left in the lurch. 'We've agreed to no surprises and no gaps in the strategic framework of Europe,' said Matthew Whitaker, US ambassador to Nato, adding he expected the review to come out in 'late summer, early fall'. Advertisement 'I have daily conversations with our allies about the process,' he said.

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals

South China Morning Post

time2 hours ago

  • South China Morning Post

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals

GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store